[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"C4 Therapeutics, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":70},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100614835","phase-2-a-study-to-evaluate-the-efficacy-of-cemsidomide--dexamethasone-in-participants-with-relapsedrefractory-multiple-myeloma-100614835",false,"NCT07284758","A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed\u002FRefractory Multiple Myeloma","A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Subjects With Relapsed\u002FRefractory Multiple Myeloma","MOMENTUM","Inclusion Criteria:\n\n1. Be willing and able to provide signed informed consent for the study.\n2. Age ≥ 18 years at the time of signed consent.\n3. Subjects must have a documented diagnosis of MM and measurable disease at enrollment.\n4. Received at least 3 prior anti-myeloma regimens (for a minimum of 2 or more consecutive cycles) that must have included an immunomodulatory drug (i.e., IKZF 1\u002F3 degrader), a proteasome inhibitor, an anti-CD38 antibody, and a T-cell engager (TCE) or chimeric antigen receptor T-cell (CAR-T) therapy, unless not available per local standard of care.\n5. Subjects need to have adequate organ function.\n6. Toxicities from prior anticancer therapies must have resolved to baseline severity or CTCAE ≤ Grade 1.\n7. Female subjects may not be pregnant or intend to become pregnant, may not breastfeed or intend to breastfeed, or donate ova during their participation in this study until 30 days after the last dose of study treatment.\n8. Male subjects must agree to use a condom when having intercourse with a person of childbearing potential during the Treatment Period and for at least 30 days after the last dose of study treatment.\n9. Male subjects must refrain from donating sperm during the Treatment Period and for 30 days after discontinuation.\n10. Subjects must refrain from donating blood during study treatment and for 30 days after discontinuation.\n\nExclusion Criteria:\n\n1. Presence of myeloma in the central nervous system (CNS).\n2. Subjects with any of the following:\n\n   * Systemic light chain amyloidosis\n   * Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy, and Skin changes (POEMS) Syndrome\n   * Myelodysplastic syndrome (MDS).\n3. Previously treated with cemsidomide.\n4. Clinically significant impaired cardiac function or cardiac disease.\n5. Thromboembolic event within 3 months prior to enrollment.\n6. Known malignancy other than study indication that has progressed or required treatment within the past 3 years.\n7. Uncontrolled active bacterial, fungal, or viral infection.\n8. Inability or difficulty swallowing tablets.\n\nNOTE: Other inclusion\u002Fexclusion criteria may apply, per protocol.","ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This is a Phase 2, open-label, single-arm, multicenter study to assess the antimyeloma activity and further characterize the safety, tolerability, PK, and PD of cemsidomide in combination with dexamethasone in participants with relapsed\u002Frefractory multiple myeloma (r\u002Fr MM).",[27,28],"Multiple Myeloma","Relapsed\u002FRefractory Multiple Myeloma",[30,31,27],"cemsidomide","dexamethasone","RECRUITING","2026-06-30",{"date":35,"type":36},"2026-07-01","ACTUAL",{"date":38,"type":36},"2026-02-18",{"date":40,"type":21},"2030-03",{"name":42,"class":43},"C4 Therapeutics, Inc.","INDUSTRY",10,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},"100614470","phase-1-a-study-to-learn-about-the-effects-of-cemsidomide-in-combination-with-elranatamab-in-relapsedrefractory-multiple-myeloma-subjects-100614470","NCT07280013","A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed\u002FRefractory Multiple Myeloma Subjects","A Phase 1B, Open-label, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of Cemsidomide in Combination With Elranatamab in Relapsed\u002FRefractory Multiple Myeloma Subjects","Inclusion Criteria:\n\n* Diagnosis of multiple myeloma as defined by IMWG criteria\n* Measurable disease based on IMWG criteria\n* Received 2-4 prior lines of therapy (escalation part) and 1-3 prior lines of therapy (expansion part) for multiple myeloma, consisting of at least 1 immunomodulatory drug (i.e., IKZF 1\u002F3 degrader)\n* ECOG performance status 0-2\n\nExclusion Criteria:\n\n* Active plasma cell leukemia, Smoldering multiple myeloma, POEMS Syndrome, systemic light chain amyloidosis, MDS\n* Stem cell transplant within 12 weeks prior to enrollment or active graft vs host disease\n* Participants with any active, uncontrolled bacterial, fungal, or viral infection\n* Prior treatment with a BCMA-directed TCE or BCMA-directed CAR-T therapy\n* Administration with an investigational product within 30 days preceding the first dose of study intervention\n* Inability or difficulty swallowing tablets, malabsorption syndrome, or any disease or medical condition significantly affecting gastrointestinal function",{"count":53,"type":21},60,[55],"PHASE1","The main purpose of the study is to understand the safety and tolerability of cemsidomide when given along with elranatamab in subjects with relapsed or refractory multiple myeloma.\n\nThe first part of the study will evaluate different dose levels of cemsidomide in combination with elranatamab in a limited number of subjects. Approximately 3 different dose levels of cemsidomide in combination with elranatamab may be explored. Once a dose level is determined safe, additional subjects may be enrolled through expansion of the dose level. This expansion will provide further exploration of the safety and evaluation of preliminary antimyeloma activity.\n\nCemsidomide will be taken orally each cycle for 14 days on\u002F14 days off (1 cycle=28 days). Elranatamab will be administered by subcutaneous injection twice a month. Dexamethasone will be administered weekly until a confirmed response but no longer than 4 cycles.",[58],"Multiple Myeloma (MM)",[60],"multiple myeloma, cemsidomide, CFT7455, elranatamab, PF-06863135, relapsed, refractory, RRMM, BCMA, bispecific antibody, BiTE, TCE, ELREXFIO","2026-04-15",{"date":63,"type":36},"2026-04-17",{"date":65,"type":36},"2026-02-06",{"date":67,"type":21},"2029-06",{"name":42,"class":43},16,""]